Atossa Therapeutics Inc [NASDAQ: ATOS] traded at a high on 2025-10-09, posting a 6.31 gain after which it closed the day’ session at $1.18.
The results of the trading session contributed to over 4352414 shares changing hands. Over the past one week, the price volatility of Atossa Therapeutics Inc stands at 10.58% while the volatility over the past one month is 5.88%.
The market cap for ATOS stock reached $152.42 million, with 129.17 million shares outstanding and 129.12 million shares in the current float. Compared to the average trading volume of 939.57K shares, ATOS reached a trading volume of 4352414 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Atossa Therapeutics Inc [ATOS]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ATOS shares is $5.69 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ATOS stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Maxim Group have made an estimate for Atossa Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 26, 2018.
The Price to Book ratio for the last quarter was 2.64, with the Price to Cash per share for the same quarter was set at 0.45.
How has ATOS stock performed recently?
Atossa Therapeutics Inc [ATOS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 28.26. With this latest performance, ATOS shares gained by 47.80% in over the last four-week period, additionally plugging by 90.29% over the last 6 months – not to mention a rise of 24.99% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ATOS stock in for the last two-week period is set at 85.12, with the RSI for the last a single of trading hit 0.0724, and the three-weeks RSI is set at 0.0542 for Atossa Therapeutics Inc [ATOS]. The present Moving Average for the last 50 days of trading for this stock 0.8309, while it was recorded at 1.0620 for the last single week of trading, and 0.8238 for the last 200 days.
Atossa Therapeutics Inc (ATOS) Capital Structure & Debt Analysis
According to recent financial data for Atossa Therapeutics Inc. ( ATOS), the Return on Equity (ROE) stands at -41.66%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -38.20%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Atossa Therapeutics Inc’s Return on Invested Capital (ROIC) is -49.78%, showcasing its effectiveness in deploying capital for earnings.
Atossa Therapeutics Inc (ATOS) Efficiency & Liquidity Metrics
Based on Atossa Therapeutics Inc’s (ATOS) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Atossa Therapeutics Inc (ATOS) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Atossa Therapeutics Inc. (ATOS) effectively leverages its workforce, generating an average of -$1914666.67 per employee. The company’s liquidity position is robust, with a Current Ratio of 9.17% and a Quick Ratio of 9.17%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Atossa Therapeutics Inc [ATOS]
With the latest financial reports released by the company, Atossa Therapeutics Inc posted -0.06/share EPS, while the average EPS was predicted by analysts to be reported at -0.06/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ATOS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Atossa Therapeutics Inc go to -15.73%.
Insider trade positions for Atossa Therapeutics Inc [ATOS]
There are presently around $21.00%, or 21.02%% of ATOS stock, in the hands of institutional investors. The top three institutional holders of ATOS stocks are: BLACKROCK INC. with ownership of 9.2 million shares, which is approximately 7.3148%. VANGUARD GROUP INC, holding 6.49 million shares of the stock with an approximate value of $$7.72 million in ATOS stocks shares; and VANGUARD GROUP INC, currently with $$3.3 million in ATOS stock with ownership which is approximately 2.2028%.
